S.R. Vavricka

Discipline

Psychologie (1) Economies et finances (1) Anthropologie biologique (1)

Type de document

Articles (16) Recensions (1)

Co-auteur

Date

Source

Mot-clé

Patients (15) Patients (15) Inflammatory bowel diseases (14) Swiss (13) maladie (12) Ulcerative colitis (12) maladie (12) cohorte (11) Human beings (10) Treatment (9) Crohn's disease (9) adulte (7) Diagnosis (7) Manufacturers' agents (7) Diagnosis (7) Commission merchants (7) adulte (7) temps (durée) (6) thérapie (6) jeune (6) Time (6) Therapeutics (6) peau (5) association (5) Social groups (5) Skin (5) Impact (5) Colitis (5) Utilization (5) Risk factors (5)

Documents écrit par S.R. Vavricka (16) | parle de S.R. Vavricka (0)

Swiss expert opinion: current approaches in faecal microbiota transplantation in daily practice.
L. Rossier et al. (25 août 2023)
Alcohol and cannabis consumption in patients with inflammatory bowel disease: prevalence, pattern of consumption and impact on the disease.
M. Martinho-Grueber et al. (1 janv. 2023)
Impact of Diagnostic Delay on Disease Course in Pediatric- versus Adult-Onset Patients with Ulcerative Colitis: Data from the Swiss IBD Cohort.
A.M. Schoepfer et al.
Abdominal pain in patients with inflammatory bowel disease: association with single-nucleotide polymorphisms prevalent in irritable bowel syndrome and clinical management.
M. Ledergerber et al. (5 févr. 2021)
Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
L. Biedermann et al. (2019)
The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort.
A. Hiller et al. (2019)
Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study.
N. Roth et al. (2019)
Expression Patterns of TNFα, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease.
S.R. Vavricka et al. (28 févr. 2018)
Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients.
T. Greuter et al. (2018)
Trends in prevalence, mortality, health care utilization and health care costs of Swiss IBD patients: a claims data based study of the years 2010, 2012 and 2014.
C. Bähler et al. (2 déc. 2017)
Extraintestinal Manifestations of Pediatric Inflammatory Bowel Disease: Prevalence, Presentation, and Anti-TNF Treatment.
T. Greuter et al.
Widely differing screening and treatment practice for osteoporosis in patients with inflammatory bowel diseases in the Swiss IBD cohort study.
S. Schüle et al.
Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases.
S. Fagagnini et al. (2017)
Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort.
M.R. Spalinger et al. (2016)
Prevalence and risk factors for therapy escalation in ulcerative colitis in the Swiss IBD Cohort Study
E. Safroneeva et al. (2015)
Extraintestinal Manifestations of Inflammatory Bowel Disease.
S.R. Vavricka et al. (2015)